Absci Corporation received a Buy upgrade following promising interim Phase 1 results for its ABS-201 drug targeting androgenetic alopecia (hair loss). The drug showed a favorable pharmacokinetic profile allowing infrequent dosing and demonstrated strong safety and tolerability. Key upcoming milestones include 13-week interim proof-of-concept data expected in the second half of 2026 and 26-week topline results in early 2027. Absci is financially strong after raising $93.6 million and plans to expand ABS-201 into endometriosis and develop ABS-202 for inflammatory and infectious diseases.
Elizabeth Crain, a director at Core Scientific, has purchased 6,000 shares of the company. This insider buying may indicate her confidence in the company's future prospects. Such moves often attract investor attention as they can signal positive expe...
Hyperscale Data has stopped Bitcoin mining to focus on AI data center services, backed by a $1.2 billion contract at its Michigan facility. The company's assets, including cash and Bitcoin, are worth nearly double its market cap, suggesting undervalu...
Casey's General Stores reported strong Q1 2026 results, surpassing analyst expectations with an EPS of $7.37 versus $6.78 estimated and revenue of $5.68 billion beating the $5.56 billion forecast. Net income rose 27.1% year-over-year to $273.7 millio...
Academy Sports and Outdoors will announce its Q2 2026 earnings on September 9, with revenue expected to rise 3.8% year-over-year to about $1.66 billion. Analysts forecast earnings per share between $2.07 and $2.12, up from $1.94 last year, indicating...
Pharvaris's experimental oral drug deucrictibant showed an 83% reduction in hereditary angioedema (HAE) attacks in a Phase 3 trial, prompting Oppenheimer to raise its price target from $50 to $75 and maintain an "Outperform" rating. The positive tria...
